AU Patent

AU2017203121B2 — Nicotine lozenge formulation

Assigned to North Star Opco Ltd · Expires 2019-02-21 · 7y expired

What this patent protects

H:\br\nterove\NRPortbl\DCCRBR\14349104_ I.doex-10/05/2017 Aspects of the present invention are directed to a nicotine lozenge for oral administration comprising: a nicotine active; at least one high viscosity, water soluble, synthetic or semi-synthetic, non-ionic polymer; and at …

USPTO Abstract

H:\br\nterove\NRPortbl\DCCRBR\14349104_ I.doex-10/05/2017 Aspects of the present invention are directed to a nicotine lozenge for oral administration comprising: a nicotine active; at least one high viscosity, water soluble, synthetic or semi-synthetic, non-ionic polymer; and at least one low 5 viscosity, water soluble, synthetic or semi-synthetic, non-ionic polymer. Lozenges of the present invention are more stable and less expensive than traditional lozenges.

Drugs covered by this patent

Patent Metadata

Patent number
AU2017203121B2
Jurisdiction
AU
Classification
—
Expires
2019-02-21
Drug substance claim
No
Drug product claim
No
Assignee
North Star Opco Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.